Although the majority of TRPC6 mutations that cause FSGS are activating, ≈25% of the reported mutations cause a loss of function [49], including a novel TRPC6 mutation (G757D) that acts as a dominant negative [49]. The gene discussed is TRPC6; the disease is focal segmental glomerulosclerosis.